170230-01-0

Basic information

• Product Name: 4-Bromo-n-methoxy-n,3-dimethylbenzamide
• CAS NO: 170230-01-0
• Molecular Formula: C₁₀H₁₂BrNO₂
• Molecular Weight: 257.01
• Mol File: 170230-01-0.mol

Chemical Properties

• CAS DataBase Reference: 4-Bromo-n-methoxy-n,3-dimethylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-n-methoxy-n,3-dimethylbenzamide(170230-01-0)
• EPA Substance Registry System: 4-Bromo-n-methoxy-n,3-dimethylbenzamide(170230-01-0)

Safety Data

• Hazardous Substances Data: 170230-01-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-Bromo-n-methoxy-n,3-dimethylbenzamide serves as a valuable intermediate in organic synthesis, particularly for the preparation of other benzamide derivatives and related compounds. Its unique structure allows for further functionalization and modification, making it a versatile building block in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-Bromo-n-methoxy-n,3-dimethylbenzamide is utilized as a research chemical for the development of new pharmaceutical agents. Its specific structural features may confer biological activities that can be harnessed for therapeutic purposes, such as modulating enzyme activity, receptor binding, or other pharmacological targets.
Used in Pharmaceutical Applications:
Although further studies are required to fully understand its potential, 4-Bromo-n-methoxy-n,3-dimethylbenzamide may have pharmaceutical applications as a lead compound for drug discovery. Its unique chemical structure could be optimized to develop new drugs with improved efficacy, selectivity, and safety profiles for the treatment of various diseases and conditions.

Upstream product

• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 13939-06-5 molybdenum hexacarbonyl 
• 7697-28-1 4-bromo-3-methylbenzoic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 21900-25-4 4-bromo-3-methylbenzoyl chloride 
• 148547-19-7 4-Bromo-3-methylbenzoic acid methyl ester 

Downstream Products

• 644984-80-5 4-(4-bromo-3-methyl-phenyl)-3-methyl-4-oxo-butyric acid methyl ester 
• 644985-05-7 4-[4-(2-benzyl-3-oxo-cyclohex-1-enylamino)-3-methyl-phenyl]-3-methyl-4-oxo-butyric acid methyl ester 
• 1253045-42-9 C₁₃H₁₅BrO 
• 1373939-98-0 5,5-dimethyl-3-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoxazol-4(5H)-one 
• 1373938-26-1 N-(5-(4-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2,6-difluorobenzamide 
• 37074-40-1 1-(4-bromo-3-methylphenyl)ethan-1-one 
• 1321848-53-6 C₁₇H₁₅Br₂NO₂ 

Relevant articles and documents

Discovery of a Novel Potent and Selective Calcium Release-Activated Calcium Channel Inhibitor: 2,6-Difluoro- N-(2′-methyl-3′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)benzamide. Structure-Activity Relationship and Preclinical Characterization

The role of calcium release-activated calcium (CRAC) channels is well characterized and is of particular importance in T-cell function. CRAC channels are involved in the pathogenesis of several autoimmune diseases, making it an attractive therapeutic target for treating inflammatory diseases, like rheumatoid arthritis (RA). A systematic structure-activity relationship study with the goal of optimizing lipophilicity successfully yielded two lead compounds, 36 and 37. Both compounds showed decent potency and selectivity and a remarkable pharmacokinetic profile. Further characterization in in vivo RA models and subsequent histopathological evaluation of tissues led to the identification of 36 as a clinical candidate. Compound 36 displayed an excellent safety profile and had a sufficient safety margin to qualify it for use in human testing. Oral administration of 36 in Phase 1 clinical study in healthy volunteers established favorable safety, tolerability, and good target engagement as measured by levels of IL-2 and TNF-α.

PIPERIDINE COMPOUNDS AS PCSK9 INHIBITORS

One aspect of the invention relates to a series of new PCSK9 inhibitor compounds comprising piperidine ring structures, including compounds of formula (I) and/or pharmaceutically acceptable salts thereof. Another aspect of the invention relates to methods of treating PCSK9 receptor related diseases comprising administration of one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.

Mo(CO)6 as a Solid CO Source in the Synthesis of Aryl/Heteroaryl Weinreb Amides under Microwave-Enhanced Condition

The facile transformation of aryl/heteroaryl nonaflates into corresponding amides via Pd-catalyzed aminocarbonylation using Mo(CO)6 as a solid CO source under microwave-enhanced condition is reported. The method was found to be tolerant with respect to a

PROCESS FOR THE PREPARATION OF VELPATASVIR

The present disclosure provides a process for the preparation of velpatasvir intermediates of formula 5. The intermediates may be further converted to velpatasvir or pharmaceutically acceptable salts thereof.

NOVEL INHIBITORS OF HEPATITIS C VIRUS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

HEPATITIS C INHIBITOR COMPOUNDS

Compounds of Formula (I): wherein R1, R2, RA, RB, Z1, Z2, Z3, Z4, Z5 and Z6 are defined herein. The compounds are useful as inhibitors of the function of NS5A protein encoded by HCV for the treatment of hepatitis C viral infection.

Discovery of biphenylketones as dual modulators of inflammation and bone loss

Biphenylketones were identified as novel inhibitors of NFκB activation. Structure-activity studies led to the identification of compound 4c, which had good potency against osteoclasts (IC50 = 0.8 μM), showed oral activity, and was able to compl

METHOD FOR PREPARING 5-HALOALKYL-4,5-DIHYDROISOXAZOLE DERIVATIVES

Disclosed is a method for preparing a compound of Formula: (1); wherein R1 is CHX2, CX3, CX2CHX2 or CX2CX3; each X is independently Cl or F; Z is optionally substituted phenyl; and Q is phenyl or 1-naphthalenyl, each optionally substituted as defined in the disclosure; comprising contacting a compound of Formula: (2).

PYRAZOLINES FOR CONTROLLING INVERTEBRATE PESTS

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof insert Formula 1 here wherein Z is N or CR2; R1 is cyano; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R17; R3 is H, cyano or -CHO; or C1-C6 alkenyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7alkylcycloalkyl, C4-C7 cycloalkylalkyl, phenyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6alkylaminocarbonyl or C3-C9dialkylaminocarbonyl, each optionally substituted with one or more substituents independently selected from R18; Q is a 5 or 6 membered saturated or unsaturated heterocycle optionally substituted; or Q is C(O)NR12R13, C(S)NR12R13, S(O)2 NR14R15 or R16; and R2, R12, R13, R14, R15, R16, R17, R18, A1, A2, A3, A4 and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.

Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: Structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109

Following the discovery of a new series of benzimidazole derivatives bearing a diarylmethyl group as inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase (HCV NS5B RdRp), we extended the structure-activity relationship (SAR) study to analogue